GILD:NSD-Gilead Sciences Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 109.98

Change

0.00 (0.00)%

Market Cap

USD 139.89B

Volume

8.15M

Analyst Target

USD 77.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-15 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 218.30B
AMGN Amgen Inc

N/A

USD 154.96B
SNY Sanofi ADR

N/A

USD 122.86B
BIIB Biogen Inc

N/A

USD 19.51B
GRFS Grifols SA ADR

N/A

USD 6.70B
AMRN Amarin Corporation PLC

N/A

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
MDCXW Medicus Pharma Ltd. Warrant

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A
SCLX Scilex Holding Company

N/A

N/A

ETFs Containing GILD

BTEC:SW iShares Nasdaq US Biotech.. 8.25 % 0.00 %

N/A

N/A
UBIO 7.77 % 0.95 %

N/A

N/A
FHI-B:CA CI Health Care Giants Cov.. 5.24 % 0.00 %

N/A

CAD 0.05B
HDLB ETRACS Monthly Pay 2xLeve.. 5.14 % 0.00 %

N/A

USD 9.02M
UDI USCF ETF Trust 4.00 % 0.00 %

N/A

N/A
JPHG:PA Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

N/A
JPHC:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 4.62M
JPHE:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 0.06B
JPHG:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 3.59M
JPHU:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 0.06B
JPNK:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 0.07B
JPNY:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 6.26B
CBUF:F iShares V Public Limited .. 3.37 % 0.00 %

N/A

N/A
MDLV EA Series Trust - Morgan .. 3.19 % 0.00 %

N/A

N/A
WHCS:SW 3.19 % 0.00 %

N/A

N/A
LGCF Themes US Cash Flow Champ.. 3.03 % 0.00 %

N/A

N/A
QQQG Pacer Nasdaq 100 Top 50 C.. 2.94 % 0.00 %

N/A

USD 3.98M
HEAL:SW iShares Healthcare Innova.. 2.66 % 0.00 %

N/A

USD 1.05B
ABFL Abacus FCF Leaders ETF 2.64 % 0.00 %

N/A

N/A
WMOT:XETRA VanEck Morningstar US Wid.. 2.51 % 0.00 %

N/A

N/A
CURE:AU Global X S&P Biotech ETF 2.41 % 0.00 %

N/A

USD 0.04B
TDOC:CA TD Global Healthcare Lead.. 2.37 % 0.00 %

N/A

CAD 0.08B
DHS:SW 2.04 % 0.00 %

N/A

N/A
DHSA:SW 2.04 % 0.00 %

N/A

N/A
RAYD Rayliant Quantitative Dev.. 1.98 % 0.00 %

N/A

USD 0.09B
CBUI:XETRA iShares MSCI World Value .. 1.88 % 0.00 %

N/A

USD 0.26B
ESMV iShares ESG MSCI USA Min .. 1.73 % 0.00 %

N/A

USD 8.52M
IQSA:LSE Invesco Quantitative Stra.. 1.65 % 0.00 %

N/A

USD 0.75B
MVEA:SW iShares Edge MSCI USA Min.. 1.60 % 0.00 %

N/A

USD 0.26B
MVEC:SW iShares Edge MSCI World M.. 1.55 % 0.00 %

N/A

USD 0.17B
MVEW:SW iShares Edge MSCI World M.. 1.55 % 0.00 %

N/A

USD 0.50B
MVWE:SW iShares Edge MSCI World M.. 1.55 % 0.00 %

N/A

USD 0.07B
WDMVO:SW 1.50 % 0.00 %

N/A

N/A
AFLG First Trust Active Factor.. 1.19 % 0.00 %

N/A

USD 0.31B
DGVA:AU Dimensional Global Value .. 1.01 % 0.00 %

N/A

N/A
EVO:CA Evovest Global Equity ETF 0.96 % 0.00 %

N/A

N/A
WELE:XETRA Amundi S&P 500 Equal Weig.. 0.59 % 0.00 %

N/A

N/A
XDEW:SW 0.25 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.33B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.04B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 2.88M
BSCK 0.00 % 0.10 %

N/A

N/A
BSCL 0.00 % 0.10 %

N/A

N/A
BSCQ Invesco BulletShares 2026.. 0.00 % 0.10 %

N/A

N/A
CBND 0.00 % 0.16 %

N/A

N/A
DVP Roundhill Acquirers Deep .. 0.00 % 0.48 %

N/A

N/A
ESGW 0.00 % 0.40 %

N/A

N/A
FCY 0.00 % 0.84 %

N/A

N/A
FCY:CA 0.00 % 0.95 %

N/A

N/A
FDL First Trust Morningstar D.. 0.00 % 0.45 %

N/A

N/A
FLAG Global X Funds 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 5.11B
IBCD 0.00 % 0.10 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.54B
MOAT VanEck Morningstar Wide M.. 0.00 % 0.49 %

N/A

N/A
ONEV SPDR® Russell 1000 Low V.. 0.00 % 0.20 %

N/A

N/A
ONEY SPDR® Russell 1000® Yie.. 0.00 % 0.20 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.02B
IVFVC 0.00 % 0.00 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.75 %

N/A

CAD 0.10B
ZFN:CA BMO SIA Focused North Ame.. 0.00 % 0.00 %

N/A

CAD 0.30B
JIGB 0.00 % 0.14 %

N/A

N/A
SPBO SPDR Portfolio Corporate .. 0.00 % 0.00 %

N/A

USD 1.55B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RJZ 0.00 % 0.75 %

N/A

N/A
SCIU 0.00 % 0.19 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
XMS:CA iShares Edge MSCI Min Vol.. 0.00 % 0.33 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
FCW:CA 0.00 % 0.90 %

N/A

N/A
SPDV AAM S&P 500 High Dividend.. 0.00 % 0.29 %

N/A

USD 0.07B
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
MINV:LSE iShares VI Public Limited.. 0.00 % 0.00 %

N/A

N/A
MVOL:LSE iShares Edge MSCI World M.. 0.00 % 0.00 %

N/A

N/A
XFVT:LSE Xtrackers FTSE Vietnam Sw.. 0.00 % 0.00 %

N/A

N/A
JPHC:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 4.64M
UBBB:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.13B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
JP40:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
JP4H:F 0.00 % 0.00 %

N/A

N/A
WTD9:F WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

USD 0.06B
WTDY:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

USD 1.08M
WTEU:F WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

USD 0.11B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.05B
JP40:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
JP4H:XETRA 0.00 % 0.00 %

N/A

N/A
WTD9:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

N/A
WTDY:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

N/A
WTEU:XETRA WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
JPGL:XETRA JPM Global Equity Multi-F.. 0.00 % 0.00 %

N/A

N/A
MVEW:XETRA iShares Edge MSCI World M.. 0.00 % 0.00 %

N/A

N/A
SCHJ Schwab 1-5 Year Corporate.. 0.00 % 0.00 %

N/A

N/A
HDIV 0.00 % 0.00 %

N/A

N/A
KVLE KFA Value Line Dynamic Co.. 0.00 % 0.00 %

N/A

USD 0.01B
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
JPGL:F JPmorgan ETFs Ireland Ica.. 0.00 % 0.00 %

N/A

N/A
CSY9:XETRA UBS (Irl) ETF plc - Facto.. 0.00 % 0.00 %

N/A

USD 0.29B
TSWE:SW VanEck Sustainable World .. 0.00 % 0.00 %

N/A

USD 0.93B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.06% 73% C 84% B
Dividend Return 1.71% 50% F 68% D+
Total Return 20.78% 82% B 85% B
Trailing 12 Months  
Capital Gain 69.04% 90% A- 90% A-
Dividend Return 4.80% 100% F 78% C+
Total Return 73.84% 90% A- 90% A-
Trailing 5 Years  
Capital Gain 47.39% 86% B+ 68% D+
Dividend Return 19.81% 100% F 63% D
Total Return 67.19% 86% B+ 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.90% 64% D 64% D
Dividend Return 10.55% 73% C 68% D+
Total Return 3.65% 64% D 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 29.06% 27% F 31% F
Risk Adjusted Return 36.29% 55% F 55% F
Market Capitalization 139.89B 75% C 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.